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Summary The effects of amiloride on the incidence and histological types of gastric cancers in Wistar rats induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), and on the labelling index and proliferative fraction of gastric mucosa were investigated. After oral treatment with MNNG for 25 weeks, rats received s.c. injections of amiloride (0.25 mg kg-' or 5.0 mg kg-' body weight) in depot form every other day until the end of the experiment. Prolonged administration of 5.0 mg kg-', but not 2.5 mg kg-' of amiloride significantly decreased the incidence of gastric cancers in Week 52. However, it did not influence the histological features of the gastric cancers. It also significantly decreased the labelling index and proliferative fraction of the antral
mucosa. These findings indicate that amiloride inhibits the development of gastric cancers, and that its effect
may be related to its effect in decreasing cell proliferation of the antral mucosa.
Stimulation of cell proliferation is associated with rapid in-
creases in Na+ influx (Schuldiner & Rozengurt, 1982), H+
efflux (Ulrich-Baker et al., 1988), and intracellular pH (Sch-
uldiner & Rozengurt, 1982; Moolenaar et al., 1983). The
intracellular pH plays an important role in controlling met-
abolism and proliferation because the activity of a large
number of metabolic enzymes, as well as the synthesis of
proteins, RNA and DNA, increases with increasing intracel-
lular pH within the physiological range (Madshus, 1988). The
intracellular pH is regulated by the amiloride-sensitive Na+/
H+ exchanger.
The diuretic drug amiloride is a potent inhibitor of the
Na+/H+ antiport (Grinstein et al., 1989) and has been
reported to inhibit tumour growth in vivo (Sparks et al.,
1983). Szolgay-Daniel et al. (1991) also observed that
amiloride inhibited growth of human glioma and human
colon carcinoma cells. Ulrich-Baker et al. (1988) found that
amiloride inhibited the post-prandial increases in jejunal
ornithine decarboxylase (ODC) activity and DNA syntheses
in the jejunum and liver. These findings suggest that
amiloride might inhibit gastric carcinogenesis. Therefore, in




Seventy-five 6-week-old male Wistar rats were purchased
from SLC (Shizuoka, Japan). The animals were housed in
stainless steel suspended wire-mesh cages under controlled
environmental conditions of 12h light and 12h darkness,
30-50% humidity, and 20-22°C. The rats were fed ad
libitum on standard laboratory pellets (Oriental Yeast, Tok-
yo, Japan).
Experimental design
The animals were given drinking water containing N-methyl-
N'-nitro-N-nitrosoguanidine (MNNG, 50 lg ml-'; Aldrich,
Milwaukee, WI) for 25 weeks. On each day of its administra-
tion, MNNG was dissolved in deionised water at a concen-
tration of mg ml-' in a cool, dark place and diluted to
50jig ml-' with tap water just before use. Rats were given
40 ml of MNNG solution each, supplied from bottles cover-
ed with aluminium foil to prevent photolysis of MNNG, and
the solution was renewed every other day. Safety precautions
were taken in use of MNNG. From Week 26, the rats were
given normal tap water ad libitum from an automatic water-
ing system and were divided randomly into three groups of
25 rats each. Group 1 was given s.c. injections of the vehicle,
plain olive oil, and Groups 2 and 3 were given s.c. injections
of amiloride (Sigma, St Louis, MO) in olive oil at 2.5 mg kg- and 5.0 mgkg-' body weight, respectively. The injec- tions were given every other day until the end of the experi-
ment in Week 52. The injections were given at various sites in
a volume of 1 mlkg-' body weight between 2 and 3 p.m.
Tissue sampling
Animals that survived for more than 47 weeks were included
in the effective numbers, because the first tumour of the
glandular stomach was found in a rat in Group 1 that died in
Week 47. All surviving animals were killed at the end of the
experiment in Week 52. All rats were autopsied, and the
stomach and other organs were carefully examined. The
stomach was opened along the greater curvature, pinned flat
on a cork mat, and fixed in Zamboni's solution (Stefanini et
al., 1967) for histological examination. The fixed stomach
was cut into longitudinal 3 mm-wide strips. The specimens
were embedded in paraffin, and 5 jtm-thick serial sections
were stained with hematoxylin and eosin. Sections were
examined without knowledge ofwhich group they were from.
Classification ofgastric cancers
Histologically, adenocarcinomas were defined as lesions in
which neoplastic glands had penetrated the muscularis muco-
sae to the submucosa or deeper layers. Adenocarcinomas
were classified as very well-differentiated, well-differentiated, and poorly differentiated, as reported previously (Tatsuta et
al., 1988).
Measurement oflabelling index andproliferativefraction of
gastric mucosa
The labelling index and proliferative fraction of the gastric
mucosa were measured in Weeks 30 and 52 with an
immunohistochemical analysis kit (Becton Dickinson Immun-
ocytometry System, Mountain View, CA) for assaying brom-
odeoxyuridine (BrdU) incorporation (Gratzner, 1982; Morstyn
et al., 1983). For this purpose, five rats in each group were
starved for 12 h and then treated s.c. with 1 ml kg-' of olive
oil (Group 1), or 2.5 mgkg-' or 5.0mgkg-' of amiloride
(Groups 2 and 3). One hour later, BrdU (20 mgkg-') was
injected i.p., and after another hour the animals were killed
with ether. For determining the labelling index and pro-
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liferative fraction of the gastric mucosa, the numbers of
BrdU-labelled and -unlabelled cells in the zone of pro-
liferating cells were counted (Eastwood & Quimby, 1983)
without knowledge of which treatment group the samples
were from. The zone of proliferating cells in the fundic
mucosa was defined as a 250-+tm rectangular area between
the highet and lowest cells in a well-oriented section. In the
antral mucosa, all cells below the highest labelled cell in each
pit-gland column were regarded as being within the zone of
proliferating cells. The total number of cells in each pit-gland
column in the antral mucosa or in a 250-1.m rectangular area
in the fundic mucosa, the number of cells in the proliferating
zone, and the number of labelled cells within the proliferating
zone were counted, and the total mucosal thickness and the
thickness of the proliferating zone were also measured. On
the basis of these measurements, the labelling index was
calculated as the number of BrdU-labelled cells/total number
of cells within the proliferating zone. The thickness of the
proliferating zone divided by the total mucosal thickness was
taken as the proliferative fraction.
Statistical analysis
Results were analysed by the Chi-square test of Fisher's exact
probability test, or by one-way analysis of variance with
Dunn's multiple comparison (Miller, 1966; Siegel, 1956;
Snedecor and Cochran, 1967). Data are shown as means
± s.e. Calculated P values of less than 0.05 were regarded as
significant.
Results
Incidence andhistological type ofgastric cancers
The body weights and incidence and histological type of
gastric cancer in each group are summarised in Table I. In
Week 52, the animals that received amiloride at higher
dosage had slightly, but not significantly lower body weights
than the untreated rats.
In control Group 1 (olive oil), gastric cancers were found
in ten of 20 rats examined. In Group 3 (amiloride 5.0 mg
kg-'), the incidence, but not the number, of gastric cancers
was significantly lower than that in Group 1. The incidence
of gastric cancers in Group 2 (amiloride 2.5 mgkg-') was
slightly lower than that in Group 1, but the difference was
not significantly.
All the tumours in the glandular stomach were identified
histologically as adenocarcinomas. Almost all were very well-
differentiated, and no poorly differentiated cancers were
found. In control Group 1 (olive oil), 75% of the tumours
were very well-differentiated adenocarcinomas and 83% were
submucosal tumours. The incidence of very well-differen-
tiated or submucosal cancers were slightly greater in Groups
2 (amiloride 2.5 mg kg-') and 3 (amiloride 5.0 mgkg-'), but
the differences were not statistically significant. All the
cancers were in the antral mucosa, and no metastases were
found.
Labelling index andproliferativefraction ofgastric mucosa
Tables II and III summarise data on the labelling index and
proliferative fraction of gastric mucosa in Weeks 30 and 52.
Table I Incidence and number of gastric cancers in MNNG-treated rats
Effective No. of rats No. of gastric
Group Body weight (g) no. of with gastric cancers per tumour-
no. Treatmenta Week 26 Week 52 rats cancer (%) bearing rat
1 Olive oil 312±4 386 6 20 10 (50) 1.2±0.1
2 Amiloride 2.5mgkg-' 313±4 382±6 17 5 (29) 1.2±0.2
3 Amiloride 5.0mgkg-' 314 5 374 5 20 3 (15)b 1.3 0.3
aTreatment; olive oil, drinking water containing MNNG for 25 weeks and then s.c. injections of the
vehicle, olive oil, only every other day; Amiloride 2.5 mgkg-' or 5.0mgkg-', drinking water
containing MNNG for 25 weeks and then s.c. injections of 2.5 mgkg-' or 5.0 mgkg-' of amiloride in
olive oil every other day. bSignificantly different from the value for Group 1 at P<0.05.
Table II Epithelial proliferation in fundic mucosa in MNNG-treated rats
No. of Thickness
No. of cells in Labelling of Mucosal Proliferative
Experimental Group labelled proliferating index proliferating thickness fraction
week no. Treatmenta cells zone (%) zone (.tm) (41m) (%)
30 1 Olive oil 31±3 103±11 30.8±1.2 102±8 423±17 24.2±1.9
2 Amiloride 2.5mgkg- 32±4 110 9 29.8±2.4 96± 8 437± 19 21.8 ± 1.2
3 Amiloride 5.0mgkg' 38±3 124±22 32.6±2.9 76±4 416±8 18.2±0.1b 52 1 Olive oil 37±3 117±12 32.0±1.1 80±5 386±8 20.8±1.1
2 Amiloride 2.5 mgkg-' 35 2 115 7 30.6 0.7 76 ± 8 386 ± 10 19.4 ± 1.5
3 Amiloride 5.0mgkg-' 32±1 110±5 29.0±1.2 68±6 378±16 18.2±0.1
aFor explanation of treatments, see Table I. bSignificantly different from the value for Group 1 at P< 0.05.
Table III Epithelial proliferation in antral mucosa in MNNG-treated rats
No. of Thickness
No. of cells in Labelling of Mucosal Proliferative Experimental Group labelled proliferating index proliferating thickness fraction
week no. Treatmenta cells zone (%) zone (JLm) (fsm) (%)
30 1 Olive oil 2.8±0.2 9.8+±Q.5 28.8± 1.3 62±4 241 5 25.6± 1.1
2 Amiloride 2.5mgkg' 2.0 0.3 7.9 ±i.0 23.2 2.5 55 ± 3 241 ± 3 22.8 1.0
3 Amiloride 5.0 mgkg-' 1.3 0.2d 6.9 0.2b 18.2 1.8c 48± lb 240 6 20.2 0.8c
52 1 Olive oil 3.0 0.2 9.7 0.3 30.6 1.4 68 4 238 5 28.6 1.2
2 Amiloride 2.5mgkg-' 2.7 0.2 9.0 0.6 29.8 1.4 63 4 253 12 25.2± 1.9
3 Amiloride 5.0 mgkg-' 1.3 O.ld 6.6 0.2d 19.0± 1.2d 49 4b 275 8 18.0± 1.2d
aFor explanation of treatments, see Table I. b-dSignificantly different from the value for Group 1: bp<0.05, Cp<0.01, dp<O.OOl.GASTRIC CANCER INHIBITION BY AMILORIDE 1013
At both times, Group 3 (amiloride 5.0 mg kg-') had
significantly lower labelling index and proliferative fraction in
the antral mucosa, but not fundic mucosa, than Group 1
(olive oil). Group 2 (amiloride 2.5 mgkg-') had slightly, but
not significantly, lower labelling index and proliferative frac-
tion in the antral mucosa than Group 1.
Discussion
In the present work, we found that amiloride inhibited gas-
tric carcinogenesis induced by MNNG in Wistar rats.
Prolonged s.c. administration of amiloride after MNNG-
treatment significantly decreased the incidence of gastric
cancers, but had no influence on their histological types in
Week 52. The MNNG is easily denatured by gastric acid.
When amiloride was given to rats during the treatment with
the carcinogen, it is very difficult to examine the true effect of
amiloride on gastric carcinogenesis, because amiloride might
influence gastric acid secretion. Therefore, in the present
study, rats were given amiloride after MNNG-treatment.
These findings indicate that amiloride has an anti-promotive
effect on gastric carcinogenesis.
The mechanism(s) of this effect is not known, but four
possibilities may be considered: inhibition ofprotein kinase C
and tyrosine kinases, inhibition of acetylcholinesterase, inhi-
bition ofadrenoceptors, and suppression of cell proliferation.
Amiloride inhibits protein kinase C (Besterman et al.,
1985) and growth factor-induced tyrosine phosphorylation
(Davis & Czech, 1985). Presek & Reuter (1987) observed that
amiloride acted as an inhibitor of protein tyrosine kinase
associated with the cellular and viral scr-gene product.
Amiloride strongly inhibited the reaction of acetylcholin-
esterase with acetylcholine in solution (Zemach et al., 1990).
Acetylcholine is a neurotransmitter and its capacity to influ-
ence the development of gastro-intestinal cancer has been
documented. We showed that prolonged administration of
the acetylcholinesterase inhibitor neostigmine after MNNG
treatment significantly decreased the incidence of gastric
cancers (Tatsuta et al., 1989c).
Amiloride at concentrations below those required for in-
hibition of the Na+/H+ exchanger is a potent antagonist of
alpha- and beta-adrenoceptors in a variety of experimental
systems (Haussinger et al., 1987). Periyasamy (1988) found
that some of the pharmacological actions of amiloride (anti-
hypertensive and diuretic effects) can be explained in part by
its regulatory effect of an alpha-adrenoceptors. Shi et al.
(1990) found that amiloride inhibited the binding of [3H]
prazosin and [3H]rauwolscine to alpha-I and alpha-2 adreno-
ceptors and concluded that it reduced alpha-adrenoceptor-
mediated responses. Norepinephrine is released by the actions
ofthe sympathetic nervous system. We examined the effect of
nialamide, a monoamine oxidase inhibitor, on the develop-
ment of gastric cancers induced by MNNG in Wistar rats,
and found that its prolonged administration significantly in-
creased the tissue norepinephrine concentration in the gastric
wall and enhanced gastric carcinogenesis (Tatsuta et al.,
1989a). Moreover, we found that chemical sympathectomy
by treatment with 6-hydroxydopamine significantly reduced
the tissue norepinephrine concentration in the gastric wall
and the incidence of gastric cancers induced by MNNG
(Tatsuta et al., 1989b).
Amiloride inhibited protein synthesis directly in stationary
phase cells, mainly through blockade of the Na+/H+ ex-
change system, with decrease of intracellular pH, in exponen-
tial growing ascites cells (Comolli et al., 1985). Yamaguchi et
al. (1986) found that amiloride inhibited irradiated Raji cell-
activated and phytohemagglutinin-P-stimulated DNA syn-
thesis. Moreover, Martel & Houdebine (1990) found that
amiloride progressively inhibited '4C-thymidine incorporation
induced by insulin, epidermal growth factor or prolactin, and
reduced basal DNA synthesis at the highest concentration
tested. Delvaux et al. (1990) observed that amiloride inhib-
ited [3H]thymidine incorporation in the same range of con-
centrations as that which inhibited Na+/H+ exchange. In the
present work, we found that prolonged administration of
amiloride significantly decreased the labelling index and pro-
liferative fraction of the antral mucosa. Expansion of the
proliferating zone may occur in the gastric mucosa of pre-
cancerous lesions (Quimby & Eastwood, 1981).
In the present study, we found that administration of
amiloride significantly decreased the labelling index of the
antral mucosa, but not fundic mucosa. Similarily, we pre-
viously reported that prolonged administration of tyrosine
methyl ester, neurotensin and vasoactive intestinal peptide
significantly increased the labelling index of the antral cells,
but they had little or no influence on the labelling index of
the fundic epithelial cells (Tatsuta et al., 1989d, 1991; Iishi et
al., 1992). However, the reason why the fundus and antrum
differ is not known. In humans and rodents, gastric cancers
usually develop in the antral mucosa. Therefore, the in-
creased labelling index of the antral epithelial cells may be
closely related to the development of gastric cancers.
Our present work showed that amiloride administration
inhibited gastric carcinogenesis induced by MNNG. The
exact mechanism of this effect is not known, but may be
related to decrease in cell proliferation of the antral epithelial
cells.
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